Endo International plc EO7.F Stock
Endo International plc Price Chart
Endo International plc EO7.F Financial and Trading Overview
Endo International plc stock price | 0.0020 EUR |
Previous Close | 0.06 EUR |
Open | 0.06 EUR |
Bid | 0 EUR x 14100 |
Ask | 0 EUR x 13400 |
Day's Range | 0.06 - 0.07 EUR |
52 Week Range | 0.03 - 0.88 EUR |
Volume | 55 EUR |
Avg. Volume | 9.46K EUR |
Market Cap | 16.7M EUR |
Beta (5Y Monthly) | 1.561619 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -9.71 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.57 EUR |
EO7.F Valuation Measures
Enterprise Value | 6.81B EUR |
Trailing P/E | N/A |
Forward P/E | 0.031838566 |
PEG Ratio (5 yr expected) | -0.26 |
Price/Sales (ttm) | 0.0076542245 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 3.121 |
Enterprise Value/EBITDA | 22.401 |
Trading Information
Endo International plc Stock Price History
Beta (5Y Monthly) | 1.561619 |
52-Week Change | -78.81% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.88 EUR |
52 Week Low | 0.03 EUR |
50-Day Moving Average | 0.09 EUR |
200-Day Moving Average | 0.12 EUR |
EO7.F Share Statistics
Avg. Volume (3 month) | 9.46K EUR |
Avg. Daily Volume (10-Days) | 9.47K EUR |
Shares Outstanding | 235.22M |
Float | 233.41M |
Short Ratio | N/A |
% Held by Insiders | 0.78% |
% Held by Institutions | 0.20% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -130.82% |
Operating Margin (ttm) | 15.47% |
Gross Margin | 53.91% |
EBITDA Margin | 13.93% |
Management Effectiveness
Return on Assets (ttm) | 3.01% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 2.18B EUR |
Revenue Per Share (ttm) | 9.28 EUR |
Quarterly Revenue Growth (yoy) | -21.00000000000000000000000000000000% |
Gross Profit (ttm) | 1.29B EUR |
EBITDA | 303.98M EUR |
Net Income Avi to Common (ttm) | -2847141120 EUR |
Diluted EPS (ttm) | -8.43 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 903.61M EUR |
Total Cash Per Share (mrq) | 3.84 EUR |
Total Debt (mrq) | 7.7B EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 2.242 |
Book Value Per Share (mrq) | -17.658 |
Cash Flow Statement
Operating Cash Flow (ttm) | 129.97M EUR |
Levered Free Cash Flow (ttm) | -122298872 EUR |
Profile of Endo International plc
Country | Germany |
State | N/A |
City | Dublin |
Address | Minerva House |
ZIP | 4 |
Phone | 353 1 268 2000 |
Website | https://www.endo.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 2861 |
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Q&A For Endo International plc Stock
What is a current EO7.F stock price?
Endo International plc EO7.F stock price today per share is 0.0020 EUR.
How to purchase Endo International plc stock?
You can buy EO7.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Endo International plc?
The stock symbol or ticker of Endo International plc is EO7.F.
Which industry does the Endo International plc company belong to?
The Endo International plc industry is Drug Manufacturers-Specialty & Generic.
How many shares does Endo International plc have in circulation?
The max supply of Endo International plc shares is 235.22M.
What is Endo International plc Price to Earnings Ratio (PE Ratio)?
Endo International plc PE Ratio is now.
What was Endo International plc earnings per share over the trailing 12 months (TTM)?
Endo International plc EPS is -9.71 EUR over the trailing 12 months.
Which sector does the Endo International plc company belong to?
The Endo International plc sector is Healthcare.